Glioma Supra Marginal Incision Trial

Study Purpose

G-SUMIT is a pilot, phase II,randomized controlled trial to evaluate the feasibility of performing a large-scale trial in patients undergoing surgery for first-time diagnosis of high grade glioma (HGG) in a surgically favorable anatomical location to answer the following: Does extending the margin of resection 1 cm beyond visible enhanced volume on MRI result in (a) an increase in overall survival? (b) result in a similar rate of "clinically-significant" neurological worsening during 30 days post surgery and quality of life at 6 and 12 months?

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 85 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Radiographic evidence of a GAD-enhancing intra-axial tumor consistent with HGG; 2. Age ≥18 ≤ 85 years; 3. Karnofsky Performance Score ≥ 60; 4. Location of tumor in a safe anatomical location and. 5. Patient or substitute decision maker (SDM) able to understand and consent to study participation.

Exclusion Criteria:

1. Multi-focal tumor, gliomatosis cerebri (≥3 lobes of the brain affected), tumors crossing the midline, or leptomeningeal enhancement; 2. Previous craniotomy for tumor excision (stereotactic biopsy is permitted); 3. Known metastatic cancer; 4. Uncorrectable coagulopathy; 5. Unable to obtain GAD-enhanced brain MRI.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04737577
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

N/A
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Sunnybrook Health Sciences Centre
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Farhad Pirouzmand, MD, MSc, FRCSCAlireza Mansouri, MD MSc FRCSCDamon Scales, MD, PhD, FRCPC
Principal Investigator Affiliation Sunnybrook Health Sciences CentrePenn State Cancer InstituteSunnybrook Health Sciences Centre
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries Canada, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

High Grade Glioma
Additional Details

This pilot, multi-centre, pragmatic randomized controlled trial is planned to simulate all aspects of a larger definitive trial comparing conventional versus supramarginal tumor resection at the time of the first surgical resection of HGG in appropriately selected patients. This pilot will help determine the ability to meet pre-specified criteria in identification, recruitment, and patient allocation, allow for refinement of eligibility criteria for optimal recruitment, confirm safety of procedure and ability to retain participants for the duration of the trial. Preliminary efficacy data will inform sample size calculations and estimation of resources required for the envisioned larger definitive trial.

Arms & Interventions

Arms

Experimental: Supramarginal resection (intervention arm)

Planned resection beyond the Gadolinium (GAD)-enhancing region extending to either at least 1 cm into non-enhancing tissue, or the nearest non-enhancing sulcal boundary/ventricle wall if these structures are closer than 1 cm.

Other: Conventional (i.e. GTR) resection

Planned resection of ≥95% of the GAD-enhancing regions of tumor without expanding the resection beyond this margin.

Interventions

Procedure: - Supramarginal resection

Tissue removal beyond the GAD-enhancing region extending to either at least 1 cm into non-enhancing tissue, or the nearest non-enhancing sulcal boundary/ventricle wall if these structures are closer than 1 cm.

Procedure: - Conventional (i.e. GTR) resection

Planned resection of ≥95% of the GAD-enhancing regions of tumor without expanding the resection beyond this margin.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

The Pennsylvania State University, University Park, Pennsylvania

Status

Recruiting

Address

The Pennsylvania State University

University Park, Pennsylvania, 16802

Site Contact

Ann Needles, BSc

[email protected]

717-531-0003 #283114

International Sites

Mackenzie Health Sciences Center, Edmonton, Alberta, Canada

Status

Recruiting

Address

Mackenzie Health Sciences Center

Edmonton, Alberta, T6G 2B7

Site Contact

Mathew Mossey

[email protected]

416-480-6100

Kingston Health Sciences Centre, Kingston, Ontario, Canada

Status

Recruiting

Address

Kingston Health Sciences Centre

Kingston, Ontario, K7L 2V7

Site Contact

Craig Spencer

[email protected]

416-480-6100

St Michael's Hospital, Toronto, Ontario, Canada

Status

Recruiting

Address

St Michael's Hospital

Toronto, Ontario, M5B 1W8

Site Contact

Clementine k Affana

[email protected]

416-480-6100

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Status

Recruiting

Address

Sunnybrook Health Sciences Centre

Toronto, Ontario,

Site Contact

Farhad Pirouzmand, MD, MSc, FRCSC

[email protected]

416-480-6100 #5263

University of Saskatchewan, Saskatoon, Saskatchewan, Canada

Status

Recruiting

Address

University of Saskatchewan

Saskatoon, Saskatchewan,

Site Contact

Jessica Grosskleg

[email protected]

[email protected]

Stay Informed & Connected